论文部分内容阅读
一、肾脏疾病与抗血小板制剂 众所周知,肾小球肾炎的发病机理主要与免疫体系有关。近年逐渐弄清了肾小球肾炎的进展、恶化及恢复与血液凝固系统、纤溶系统、血小板系统、kinin-kallikrein系、补体系密切相关。因此,采用抗凝固疗法、纤溶疗法治疗肾病取得了一定的成绩。最近各种抗血小板制剂也进入了治疗肾炎的领域。 (一) 肾病与血小板有关 在受损的肾小球中可发现血小板及血小板有关物质;血小板可成为肾小球肾炎的原因,且血中的免疫复合物(IC)可激活血小板;无论在体内或体外,肾小球肾炎患者的血小板皆可被激活;某种肾炎可出现血小板数目减少和血小板存活率降低的现象;有些肾炎采用抗血小板疗法有效。
First, the kidney disease and antiplatelet agents As we all know, the pathogenesis of glomerulonephritis mainly with the immune system. In recent years, gradually clarify the progress of glomerulonephritis, deterioration and recovery and blood coagulation system, fibrinolytic system, platelet system, kinin-kallikrein line, complement system is closely related. Therefore, the use of anticoagulant therapy, fibrinolysis treatment of kidney disease has made some achievements. Recently, various anti-platelet agents have also entered the field of treatment of nephritis. (A) of kidney disease and platelets in the damaged glomerular platelets and platelet-related substances can be found; platelets can be the cause of glomerulonephritis, and immune complexes in the blood (IC) can activate platelets; both in vivo Or in vitro, glomerulonephritis in patients with platelets can be activated; some nephritis may appear to reduce the number of platelets and platelet survival decreased; some nephritis with antiplatelet therapy is effective.